Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, double-blind, placebo-controlled investigation to evaluate the performance and safety of SPL7013 Nasal Spray in non-hospitalised patients with COVID-19

Next Previous
Search
Trial Profile

A randomized, double-blind, placebo-controlled investigation to evaluate the performance and safety of SPL7013 Nasal Spray in non-hospitalised patients with COVID-19

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 07 Nov 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Astodrimer (Primary)
  • Indications COVID 2019 infections
  • Focus Therapeutic Use
  • Sponsors Starpharma

    • Most Recent Events

    • 25 Sep 2023 According to ISRCTN: Current Controlled Trials record, Recruitment completion expected on 22 Sep 2023.
    • 18 Sep 2023 Planned End Date changed from 31 Oct 2023 to 30 Sep 2023.
    • 18 Sep 2023 Status changed from Active, no longer recruiting to recruiting

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top